SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry - 28/03/23
, Josep Tabernero, ProfPhD c, Uma Mukherjee, PhD d, Ramon Salazar, PhD e, Anna Sureda, PhD f, Clara Maluquer, MD f, Daniela Ferrante, PhD g, Mark Bower, ProfPhD j, Rachel Sharkey j, Oriol Mirallas, MD c, Andrea Plaja, MD k, Marc Cucurull, MD k, Ricard Mesia, MD k, Alessia Dalla Pria, MD j, Thomas Newsom-Davis, PhD j, Mieke Van Hemelrijck, ProfPhD l, m, Ailsa Sita-Lumsden, PhD l, Eleanor Apthorp, BSc n, Bruno Vincenzi, ProfPhD b, o, Giuseppina Rita Di Fazio, MD b, o, Giuseppe Tonini, ProfPhD b, o, Francesco Pantano, PhD b, o, Alexia Bertuzzi, MD p, Sabrina Rossi, MD p, Joan Brunet, PhD q, Matteo Lambertini, PhD r, s, Paolo Pedrazzoli, MD t, u, Federica Biello, MD h, x, Francesca D’Avanzo, MD h, x, Alvin J X Lee, PhD v, Marianne Shawe-Taylor, MRes v, Lucy Rogers, MD v, Cian Murphy, PhD v, Lee Cooper, MD v, Ramis Andaleeb, MD v, Saira Khalique, PhD v, Samira Bawany, MD v, Sarah Ahmed, MD v, M Carmen Carmona-García, MD q, Roser Fort-Culillas, MD q, Raquel Liñan, MD q, Federica Zoratto, MD w, Gianpiero Rizzo, MD u, Marta Perachino, MD r, s, Kris Doonga, MD j, Gianluca Gaidano, ProfMD i, x, Riccardo Bruna, MD i, x, Andrea Patriarca, MD i, x, Clara Martinez-Vila, MD y, Ignacio Pérez Criado, MD y, Raffaele Giusti, MD z, Francesca Mazzoni, MD aa, Lorenzo Antonuzzo, PhD aa, Armando Santoro, ProfMD p, ab, Alessandro Parisi, MD ac, Paola Queirolo, MD ad, Avinash Aujayeb, MD ae, Lorenza Rimassa, MD p, ab, Nikolaos Diamantis, PhD d, Rossella Bertulli, MD af, Claudia A M Fulgenzi, MD a, o, Antonio D’Alessio, MD a, h, Isabel Ruiz-Camps, PhD ag, Nadia Saoudi-Gonzalez, MD c, David Garcia Illescas, MD c, Irene Medina, MD ah, Laura Fox, MD ah, Alessandra Gennari, MD h, x, Juan Aguilar-Company, MD c, ag, David J Pinato, PhD a, hon behalf of the
OnCovid study group
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Summary |
Background |
COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care. We aimed to investigate whether previous immunisation affects long-term sequelae in the context of evolving variants of concern of SARS-CoV-2.
Methods |
OnCovid is an active registry that includes patients aged 18 years or older from 37 institutions across Belgium, France, Germany, Italy, Spain, and the UK with a laboratory-confirmed diagnosis of COVID-19 and a history of solid or haematological malignancy, either active or in remission, followed up from COVID-19 diagnosis until death. We evaluated the prevalence of COVID-19 sequelae in patients who survived COVID-19 and underwent a formal clinical reassessment, categorising infection according to the date of diagnosis as the omicron (B.1.1.529) phase from Dec 15, 2021, to Jan 31, 2022; the alpha (B.1.1.7)–delta (B.1.617.2) phase from Dec 1, 2020, to Dec 14, 2021; and the pre-vaccination phase from Feb 27 to Nov 30, 2020. The prevalence of overall COVID-19 sequelae was compared according to SARS-CoV-2 immunisation status and in relation to post-COVID-19 survival and resumption of systemic anticancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974.
Findings |
At the follow-up update on June 20, 2022, 1909 eligible patients, evaluated after a median of 39 days (IQR 24–68) from COVID-19 diagnosis, were included (964 [50·7%] of 1902 patients with sex data were female and 938 [49·3%] were male). Overall, 317 (16·6%; 95% CI 14·8–18·5) of 1909 patients had at least one sequela from COVID-19 at the first oncological reassessment. The prevalence of COVID-19 sequelae was highest in the pre-vaccination phase (191 [19·1%; 95% CI 16·4–22·0] of 1000 patients). The prevalence was similar in the alpha–delta phase (110 [16·8%; 13·8–20·3] of 653 patients, p=0·24), but significantly lower in the omicron phase (16 [6·2%; 3·5–10·2] of 256 patients, p<0·0001). In the alpha–delta phase, 84 (18·3%; 95% CI 14·6–22·7) of 458 unvaccinated patients and three (9·4%; 1·9–27·3) of 32 unvaccinated patients in the omicron phase had sequelae. Patients who received a booster and those who received two vaccine doses had a significantly lower prevalence of overall COVID-19 sequelae than unvaccinated or partially vaccinated patients (ten [7·4%; 95% CI 3·5–13·5] of 136 boosted patients, 18 [9·8%; 5·8–15·5] of 183 patients who had two vaccine doses vs 277 [18·5%; 16·5–20·9] of 1489 unvaccinated patients, p=0·0001), respiratory sequelae (six [4·4%; 1·6–9·6], 11 [6·0%; 3·0–10·7] vs 148 [9·9%; 8·4–11·6], p=0·030), and prolonged fatigue (three [2·2%; 0·1–6·4], ten [5·4%; 2·6–10·0] vs 115 [7·7%; 6·3–9·3], p=0·037).
Interpretation |
Unvaccinated patients with cancer remain highly vulnerable to COVID-19 sequelae irrespective of viral strain. This study confirms the role of previous SARS-CoV-2 immunisation as an effective measure to protect patients from COVID-19 sequelae, disruption of therapy, and ensuing mortality.
Funding |
UK National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 24 - N° 4
P. 335-346 - avril 2023 Regresar al número
Artículo precedente
- Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
- Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Leanna Cheung, Kim N Chi, Simon Chowdhury, Mark Frydenberg, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, Martin Neil Reaume, Shahneen K Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G Williams, Diana Winter, Sonia Yip, Alison Y Zhang, Robert R Zielinski, Ian D Davis, ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle Cronk, Katharine Cuff, Ian D Davis, Anthony Dowling, Mark Frydenberg, Matthew George, Lisa Horvath, Elizabeth Hovey, Anthony Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Stevanovic, Martin Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, Holly Campbell, Kim Chi, Joseph Chin, Edmond Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sebastien Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Eric Vigneault, Pawel Zalewski, John McCaffrey, Ray McDermott, Patrick Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile O’Donnell, Jim Edwards, Peter Fong, Alvin Tan, Simon Chowdhury, Simon Crabb, Omar Khan, Vincent Khoo, Graham Macdonald, Heather Payne, Angus Robinson, Jonathon Shamash, John Staffurth, Carys Thomas, Alastair Thomson, Christopher J Sweeney
- Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial
- Marc-Oliver Grimm, Christine Barbara Grün, Günter Niegisch, Martin Pichler, Florian Roghmann, Bernd Schmitz-Dräger, Gustavo Baretton, Marc Schmitz, Christian Bolenz, Susan Foller, Katharina Leucht, Ulrike Schumacher, Martin Schostak, Johannes Meran, Wolfgang Loidl, Friedemann Zengerling
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.